Description of the medicine: Cytarabinum (Cytarabinum)
CITARABIN (Cytarabinum). 4-Amino-1-bD-arabinofuranosyl-2 (1H) -pyrimidinone, or 1-bD-arabino-furanosylcytosine.
Synonyms: Alexa, Cytosar, Alexan, Aracytidine, Cytarabine, Cytosar, Cytosinarabinosid.
White crystalline powder. By structure and action refers to antimetabolites - analogues of pyrimidine.
Applied with acute leukemia (mostly non-lymphoblastic forms) and blast crises of chronic myelogenous leukemia.
Enter cytarabine intravenously (drip or infusion), subcutaneously and intrathecally.
The drug can be used alone and in combination with other cytostatic agents (cyclophosphamide, vincristine, thioguanine, L-asparaginase, rubomycin, carminomycin) and prednisolone. The effectiveness of the drug is determined by taking into account the dynamics of changes in the number of blast cells in the peripheral blood and bone marrow.
The daily dose of cytarabine is 100 mg per 1 m 2 of the body surface, the course dose for all routes of administration is 500-1000 mg. In elderly patients or with reduced hematopoies reserves, lower doses of the drug are used - 50 to 75 mg / m 2.
Immediately before use, the contents of the vial are dissolved with an isotonic sodium chloride solution or with sterile water for injection (for intravenous administration in 400 ml, for subcutaneous and intrathecal in 1 ml).
Intravenously daily dose (100 mg / m 2) of cytarabine is administered in the form of two dropwise transfusions slowly (3 hours) with an interval of 10 hours.
With the infusion, the daily dose of the drug is administered continuously for 24 hours.
Subcutaneously cytarabine is used at 20 mg / m 2 2 - 3 times a day.
Assign daily for 4 - 7 days or more (up to 10 days). In total, 4-7 courses are conducted at intervals of 10-14 days or more.
Intrathecal, for the prevention of neuroleukemia, the drug is administered every 3 days for 15 days in a single dose of 20 mg / m 2 (usually in combination with methotrexate at a dose of 12.5 mg / m 2). To determine the individual tolerability of the drug in these cases, it is possible to gradually increase the single dose from 3 to 20 mg / m 2. Total spend 4 - 7 courses. Intervals between the courses are 10 - 14 days or more.
With the use of cytarabine, leukopenia, thrombocytopenia, anemia, megaloblasticosis, nausea, vomiting, loss of appetite, abdominal pain, diarrhea, inflammation and ulceration of the oral mucosa, thrombophlebitis, liver dysfunction, rarely - renal dysfunction (in this case should be reduced Dose or cancel the drug).
Treatment should be carried out under the control of the number of white blood cells (daily or every other day) and the hematopoietic function of the bone marrow (before and after each course of therapy). It is necessary to monitor the function of the liver and kidneys.
The drug is contraindicated in severe violations of the liver and kidneys, with pregnancy.
Form release: lyophilized powder or porous mass in bottles of 0.1 grams in a package of 10 bottles.
Storage: List B. At temperatures not higher than +5 C.